Aspirin drug combo reduces dialysis risk
This article was originally published in The Tan Sheet
Executive Summary
Aspirin combined with the anti-platelet drug dipyridamole extends the life of artery-vein access grafts used for hemodialysis, according to a study of 649 participants with new AV grafts conducted by the Dialysis Access Consortium. The drug combination reduces loss of primary unassisted graph patency by 18 percent and the rate of developing significant stenosis by 28 percent, compared to a placebo, according to the National Institutes of Health. The release says most AVs fail because of clotting around blood vessels that narrow at the graft site
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.